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Fluid and HCO3
− secretion is a vital function of secretory epithelia,
involving basolateral HCO3
− entry through the Na+-HCO3
− cotrans-
porter (NBC) NBCe1-B, and luminal HCO3
− exit mediated by cystic
ﬁbrosis transmembrane conductance regulator (CFTR) and solute
carrier family 26 (SLC26) Cl−/HCO3
− exchangers. HCO3
− secretion
is highly regulated, with the WNK/SPAK kinase pathway setting
the resting state and the IRBIT/PP1 pathway setting the stimulated
state. However, we know little about the relationships between the
WNK/SPAK and IRBIT/PP1 sites in the regulation of the transporters.
The ﬁrst 85 N-terminal amino acids of NBCe1-B function as an auto-
inhibitory domain. Here we have identiﬁed a positively charged
module within NBCe1-B(37-65) that is conserved in NBCn1-A and
all 20 members of the NBC superfamily except NBCe1-A. This mod-
ule is required for the interaction and activation of NBCe1-B and
NBCn1-A by IRBIT and their regulation by phosphatidylinositol 4,5-
bisphosphate (PIP2). Activation of the transporters by IRBIT and PIP2
is nonadditive but complementary. Phosphorylation of Ser65 medi-
ates regulation of NBCe1-B by SPAK, and phosphorylation of Thr49
is required for regulation by IRBIT and SPAK. Sequence searches
using the NBCe1-B regulatory module as a template identiﬁed a ho-
mologous sequence in the CFTR R domain and Slc26a6 sulfat trans-
porter and antisigma factor antagonist (STAS) domain. Accordingly,
the R and STAS domains bind IRBIT, and the R domain is required for
activation of CFTR by IRBIT. These ﬁndings reveal convergence of
regulatory modalities in a conserved domain of the NBC that may
be present in other HCO3
− transporters and thus in the regulation of
epithelial ﬂuid and HCO3
− secretion.
Fluid and HCO3
− secretion is a vital function of secretory
epithelia that involves basolateral HCO3
− entry through the
Na+-HCO3
− cotransporter (NBC) NBCe1-B and luminal HCO3
−
exit mediated by the concerted activity of cystic ﬁbrosis trans-
membrane conductance regulator (CFTR) and members of the
solute carrier family 26 (SLC26) transporter family (1). HCO3
−
secretion is osmotically active owing to an inﬂux of Na+-2HCO3
−
(2, 3) and the exchange of Cl−/2HCO3
− by Slc26a6 (4, 5), resulting
in net osmolyte secretion in the form of HCO3
−. HCO3
− secretion
is a highly regulated activity, with several signaling pathways con-
verging to regulate key transporters activity to tune the secretion
(1); however, very little is known about the molecular mechanisms
that regulate ﬂuid and HCO3
− secretion, particularly the regula-
tion of NBCe1-B.
NBCe1-B was originally designated pancreatic NBC 1 (6) and
was later renamed NBCe1-B as a member of the electrogenic
NBCe1 subfamily of the Na+-coupled bicarbonate transporter
(NCBT) superfamily (2, 3). NBCe1-B is is expressed in the
basolateral membrane of most secretory epithelia, including the
pancreas, salivary glands, airway, and intestines (1). The NCBTs
encompass 13 transmembrane domains with varying cytoplasmic
N and C termini among the isoforms (3). Most members of the
NCBT superfamily have a unique N terminus (the ﬁrst 85 resi-
dues in NBCe1-B) (7). This domain has been shown to function
as an autoinhibitory domain (AID) in NBCe1-B (8–10). Very
little is known about the regulation of NBCe1-B or other
members of the superfamily beyond that NBCe1-B may be mod-
estly activated by cAMP (11, 12), although inhibition of NBCe1-B
by cAMP was subsequently reported by the same group (13).
NBCe1-B appears to be constitutively phosphorylated by protein
kinase A in Thr49 (11); however, its role in activation of the
transporter is not clear, given that both the T49A and T49D
mutations were found to prevent activation by cAMP (11). Acti-
vation of NBCe1-B and NBCe1-C by intracellular Ca2+ through
an unknown mechanism was reported recently (5). NBCe1-A is
activated by phosphatidylinositol 4,5-bisphosphate (PIP2) (14), but
direct activation of NBCe1-B and NBCe1-C by PIP2 has not been
examined. The site of interaction of PIP2 in regulating the activity
of any NCBT family member remains to be determined.
NBCe1-B (9, 10, 15, 16) and NBCe1-C (17) are potently acti-
vated by the inositol 1,4,5-triphosphate (IP3) receptors binding
protein released with IP3 (IRBIT) and are inhibited by the with no
lysine kinase (WNK) and Ste20-related proline alanine rich kinase
(SPAK) (15). IRBIT also regulates CFTR (15, 16) and sodium-
hydrogen exchanger 3 (NHE3) (18). IRBIT activates NBCe1-B by
recruiting protein phosphatase 1 (PP1), reversing inhibition by the
WNK/SPAK pathway through dephosphorylation of NBCe1-B
(15) and relief of inhibition by the AID (9, 10, 15, 16). The WNKs
function as scaffolds to recruit SPAK to NBCe1-B, which in turn
phosphorylates the transporter at unknown sites. Similarly, the
site of IRBIT–AID interaction is unknown. Deletion of the
ﬁrst 16 residues of NBCe1-B prevents activation by IRBIT (9),
although the effect of this truncation on IRBIT binding is
unclear. On the other hand, an in vitro binding assay revealed
binding of IRBIT to NBCe1-B(1-62), but not to NBCe1-B(1-
37) (10). This ﬁnding suggests that the IRBIT binding site may
be located within NBCe1-B(37-62); however, the possible
binding of IRBIT to NBCe1-B(37-62) or a site within has not
yet been examined.
The extent to which these pathways regulate other members of
the NBC family is unknown, although IRBIT may activate an un-
speciﬁed member of the NBCn1 subfamily (2). The NBCn1 sub-
family was established with the discovery of NBC3, later renamed
NBCn1-A. NBCn1-A is a widely expressed electroneutral NBC (3,
7) that mediates HCO3
− salvage in secretory epithelia (19, 20).
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Given that sequence analysis has shown signiﬁcant conservation of
the N termini of NBCe1-B and NBCn1-A, we deemed it useful to
compare the regulation of these NBCs by IRBIT/PP1, PIP2, and
SPAK to evaluate the generality of this regulation. In the present
studies, we also investigated whether these multiple regulatory
pathways converge on the same domain to regulate the transporters.
We have identiﬁed a positively charged domain within NBCe1-B
(37-65) that is conserved in NBCn1-A and most members of the
NCBT superfamily and is required for interaction and activation
of the transporters by IRBIT. The same domain mediates regu-
lation of NBCe1-B and NBCn1-A by PIP2. Importantly, activa-
tion of the transporters by IRBIT and PIP2 is nonadditive but
complementary. Phosphorylation of Ser65 within this domain
mediates regulation of NBCe1-B by SPAK, and phosphorylation
of Thr49 within NBCe1-B(37-65) is required for regulation by the
activator IRBIT and the inhibitor SPAK. Moreover, a sequence
search using the conserved module identiﬁed a similar module in
Slc26a6 and CFTR that is required for regulation of CFTR by
IRBIT. These ﬁndings reveal convergence of regulatory modali-
ties in the AID of the NBCs and thus in the regulation of epi-
thelial ﬂuid and HCO3
− secretion.
Results and Discussion
Current driven by electrogenic Na+-HCO3
− cotransporters has
been previously reported only in Xenopus oocytes. However,
several regulatory functions are absent or are different in the
oocytes. Thus, we expressed NBCe1-B in HeLa cells and de-
termined the NBCe1-B–mediated current and changes in in-
tracellular pH (pHi) to study regulation of NBCe1-B activity in
mammalian cells. Exposing HeLa cells transfected with NBCe1-
B to solution containing 28 mM HCO3
− resulted in a small
outward current that was absent from cells transfected with GFP
(Fig. S1 A and D). The current was markedly increased by IRBIT
(Fig. S1A) and inhibited by 0.5 mM diisothiocyanostilbene-2,2′-
disulfonic acid (DIDS), an NBCe1-B inhibitor (Fig. S1 C and D).
Similar results were observed when NBCe1-B activity was
measured as the inﬂux of Na+-dependent HCO3
− into acidi-
ﬁed cells (Fig. S1 E and F).
IRBIT and PIP2 Sites. The main goal of the present work was to
identify the sites for regulation of the NBCs by IRBIT, PIP2, and
the WNK/SPAK pathway and the relationships among these sites.
Sites for interaction and regulation by PIP2 have been reported for
several transporters, most of which involve clusters of positively
charged residues (21). Sequence analysis of all members of the
NCBT superfamily, in which the N termini show signiﬁcant ho-
mology, identiﬁed a conserved cluster of positively charged resi-
dues (Fig. S2A). To examine how this sequence, which is within the
AID of NBCe1-B, may interact with IRBIT and PIP2, we de-
veloped a model of the entire NBCe1-B N terminus, consisting of
400 residues (Fig. S2B). The N terminus outside the AID is based
on the crystal structure of anion exchanger 1 (AE1) (22) and is
predicted with high conﬁdence. A similar analysis that reached the
same conclusion was reported previously (11). The AID (shown in
turquoise in Fig. S2B) was predicted with less conﬁdence by
ROBETTA using a de novo modeling source. The highly charged
cluster (highlighted in orange) is also shown in Fig. 1A. Deletion of
residues 40–62 in NBCe1-B eliminated NBCe1-B–IRBIT in-
teraction, and NBCe1-B became fully active owing to removal of
autoinhibition and was no longer activated by IRBIT (Fig. S3).
Thus, we focused on the region around the three arginines high-
lighted in red in Fig. 1A and Fig. S2B and eventually on the three
arginines themselves, which are conserved in almost all NBC iso-
forms (Fig. S2A).
Single R/A mutations had no effect on the NBCe1-B–IRBIT
interaction, whereas the double R42/43A signiﬁcantly reduced and
the the triple R42/43/44A (3R/3A mutant) nearly eliminated this
interaction (Fig. 1 B and C). As expected, the 3R/3A mutant was
not activated by IRBIT (Fig. 1D and Fig. S4 A and B). NBCe1-B
was activated by PIP2, but this activation was inﬂuenced by the
intracellular ion composition (Fig. 1E). Dialysis with a solution
in which the major salt was Cs+-aspartate− prevented activation by
PIP2, and the use of a KCl-based solution resulted in variable cur-
rent. The best results were obtained with an N-methyl-D-glucamine
(NMDG)-based solution. Notably, IRBIT and PIP2 activated
NBCe1-B to the same extent, and the activation was nonadditive.
Importantly, the 3R/3A mutant was not activated by PIP2. To
assay the regulation of NBCe1-B by PIP2 under closer
to physiological conditions, we examined activation of NBCe1-
B–mediated HCO3
− transport by PIP2 delivered with the aid of
a carrier peptide (Methods). We found that the triple mutant was
not activated by IRBIT or PIP2, that PIP2 activated NBCe1-B, and
that the activation by IRBIT and PIP2 was nonadditive (Fig. S4 C
and D). The assay shown in Fig. S4 can be used to examine reg-
ulation of the electroneutral NBCn1-A by PIP2 (see below).
SPAK Phosphorylation Site. Given that IRBIT antagonizes and
reverses the inhibitory effect of SPAK (15), we asked whether
NBCe1-B(3R/3A) is still inhibited by SPAK. Surprisingly, although
no R/A mutant had an effect on the interaction of NBCe1-B with
SPAK (Fig. 2A), inhibition of NBCe1-B(3R/3A) by SPAK was lost
(Fig. 2 B and C). We previously showed that SPAK inhibits
NBCe1-B by reducing its surface expression. This mechanism is
conﬁrmed in Fig. 2D, which also shows that surface expression of
NBCe1-B(3R/3A) was unaffected by SPAK.
These unexpected ﬁndings raise the possibility that SPAK may
act by phosphorylating Ser/Thr residues within the AID. Fig. 3A
shows all of the Ser/Thr residues in NBCe1-B, with those in
green having no effect and those in blue (also shown as blue
Fig. 1. The NBCe1-B site mediating regulation by IRBIT and PIP2. (A)
Alignment of the conserved highly charged N-terminal modules in NBCe1-B,
NBCn1-A, and NDCBE-A. The arginines mutated in this study are highlighted
in red. (B and C) Representative blot showing the effects of the single,
double, and triple arginine mutations on the NBCe1-B–IRBIT interaction (B)
and mean ± SEM of four experiments (C). Current measured in HeLa cells
expressing the NBC of interest. (D) Activation of NBCe1-B current by IRBIT
and markedly reduced activation of NBCe1-B(3R/3A). (E) NBCe1-B current in
different pipette solutions. Where indicated, the pipette solution also in-
cluded 10 μM PIP2. Note that IRBIT and PIP2 activated NBCe1-B similarly, and
that activation by PIP2 was eliminated the 3R/3A mutation.
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sticks in the model in Fig. S2B) affecting the activity and/or
regulation of NBCe1-B by SPAK. Fig. S5A shows the behavior of
NBCe1-B(S79A) as an example of a mutant that behaves like
WT NBCe1-B. The traces in Fig. 3 B–D and the summaries in
Fig. 3E show the effect of SPAK on NBCe1-B(S65). Ser65 be-
haved as was expected by a primary serine phosphorylated by
SPAK. NBCe1-B(S65A) increased basal activity and was not
inhibited by SPAK, suggesting that NBCe1-B is partially inhibited
by SPAK under basal conditions, as has been reported for siSPAK
in HEK cells and in the pancreatic duct (15). On the other hand,
the activity of NBCe1-B(S65D) was lower than that of WT
NBCe1-B, reduced to the activity measured with NBCe1-B treated
with SPAK, and was not further inhibited by SPAK. The NBCe1-
B(S65D) mutation did not prevent activation by IRBIT.
Thr49 is another NBCe1-B–phosphorylatable residue that af-
fected inhibition by SPAK. However, mutations of Thr49 did not
result in the behavior expected from a primary SPAK site. Thr49
was previously shown to be constitutively phosphorylated by
PKA (11). The NBCe1-B(T49A) and NBCe1-B(T49D) mutants
had no effect on basal activity, but similarly prevented inhibition
by SPAK and stimulation by IRBIT, rather than demonstrating
increased basal activity by NBCe1-B(T49A) and reduced basal
activity by NBCe1-B(T49D), while preventing the effects of SPAK
(Fig. S5). Thr49 lies within the positively charged cluster, and thus
the prevention of the effects of both IRBIT and SPAK by
Thr49Ala and Thr49Asp suggests that an intact cluster is required
for both activation by IRBIT and inhibition by SPAK. Further
support for this idea is provided by the action of the NBCe1-B
(T49A/S65A) doublemutant, which prevented inhibition by SPAK
and activation by IRBIT (Fig. 3E).
To further analyze the effect of the Ser/Thr mutations, we ex-
amined the effect of the mutations on NBCe1-B phosphorylation
and its interaction with SPAK and IRBIT; the results are shown
in Fig. 3 F–H and Fig. S6. Control experiments showed that the
Ser/Thr mutations had no apparent effect on the interaction
of NBCe1-B with SPAK (Fig. S6A) or IRBIT (Fig. S6B). The
Ser65Ala mutation prevented reduction of NBCe1-B surface ex-
pression by SPAK (Fig. 3F), accounting for the lack of NBCe1-B
(S65A) activity inhibition by SPAK. The NBCe1-B(S65A) and
NBCe1-B(S79A) mutations had no effect on basal phosphoryla-
tion, whereas in all experiments the Thr49Ala mutation increased
the basal phosphorylation of NBCe1-B to nearly the level observed
with SPAK (Fig. 3G). The reason for the increased phosphoryla-
tion or the residue(s) that are phosphorylated to increase phos-
phorylation of NBCe1-B(T49A) is not known at present.
Accordingly, to best determine the effect of the mutations on
NBCe1-B phosphorylation by SPAK, we evaluated the change in
phosphorylation caused by SPAK (Fig. 3H), which indicated that
SPAK did not phosphorylate NBCe1-B(T49A) or NBCe1-B
(S65A) but phosphorylated the control NBCe1-B(S79A) similar to
NBCe1-B. Taken together, the ﬁndings presented in Fig. 3 identify
phosphorylation of Ser65 by SPAK as essential to the regulation of
the surface expression and thus also the activity of NBCe1-B.
General Role of the Charged Cluster. The presence of a similar motif
in the N terminus on NBCe1-B, NBCn1-A, and Na+-dependent
Fig. 2. Effects of the arginine mutations on inhibition of NBCe1-B by SPAK.
(A) The arginine mutations have no effect on the NBCe1-B–SPAK interaction.
(B and C) NBCe1-B(3R/3A) is not inhibited by SPAK. (D) The 3R/3A mutation
prevents reduced surface expression of NBCe1-B by SPAK.
Fig. 3. Identiﬁcation of the SPAK phosphorylation
site in the N terminus of NBCe1-B. (A) Alignment of
the N terminus 80–90 residues of NBCe1-B, NBCn1-
A, and NDCBE-A. The arrows indicate the Ser/Thr
residues mutated in this study. They were selected
based on conservation among the transporters
(Ser12) known to be phosphorylated (Thr49), to be
close to Ser65 (Ser68), or to be part of a cluster
(S79). The green arrows mark the Ser residues that
were mutated and had no effect on activity. Mu-
tation of the residues in blue altered the effect of
IRBIT and/or SPAK. (B–E) Example traces for WT (B)
and the indicated mutants (C and D) and the sum-
mary of the indicated number of experiments (E)
for the NBCe1-B mutants alone (black column), and
coexpressed with SPAK (green columns) or IRBIT
(red columns). *P < 0.05 or better relative to the re-
spective WT NBCe1-B. #P < 0.05 or better with IRBIT
and SPAK. In the case of NBCe1-B(T49A/S65A), the P
level is relative to the indicated single mutants. (F–H)
The effect of Ser/Thr mutation on phosphorylation of
NBCe1-B by SPAK. The S65A mutation prevented the
reduction of NBCe1-B surface expression by SPAK (F),
and the T49A and S65A mutations markedly reduced
phosphorylation of NBCe1-B by SPAK.








− exchanger (NDCBE-A) allowed us to examine the
generality of regulation by the IRBIT/PP1, PIP2, and WNK/SPAK
pathways. To do so, we ﬁrst established the activation of NBCn1-A
by IRBIT and PP1, inhibition by dominant-negative IRBIT
(IRBITΔPEST and IRBITΔC-C) and inhibitors of PP1 (I2 and
tautomycin), and inhibition by SPAK and its reversal by IRBIT and
PP1 (Fig. 4). These regulatory features are similar to those for
NBCe1-B (15). We then analyzed the effects of mutating the three
conserved arginines on regulation by IRBIT, PIP2, and SPAK. We
found that NBCn1-A was activated by PIP2, and that activation by
PIP2 was nonadditive with activation by IRBIT (Fig. 5 A and C).
Signiﬁcantly, mutation of the conserved 56RRR58 to Ala elimi-
nated activation by IRBIT and PIP2 (Fig. 5 B and C) and markedly
reduced theNBCn1-A–IRBIT interaction (Fig. 5D). Finally, SPAK
reduced the surface expression of NBCn1-A (Fig. 5E), accounting
for the inhibition of NBCn1-A activity by SPAK (Fig. 4). The effect
of SPAK on surface expression was reversed by IRBIT and pre-
vented by the 3R/3A mutation (Fig. 5E). The WNK/SPAK and
IRBIT/PP1 pathways likely regulate the function of NDCBE as
well. These ﬁndings suggest a general regulatory mechanism of the
Na+-HCO3
− cotransport with AID that is mediated by the con-
served charged motif.
Considering that the WNK/SPAK and IRBIT/PP1 pathways
regulate CFTR activity (15, 16), we asked whether the module
identiﬁed in the NBCs AID is present in CFTR and other trans-
porters. A sequence search using the module as a template iden-
tiﬁed the sequences shown in Fig. 6A in the CFTR R domain and
Slc26a6 sulfat transporter and antisigma factor antagonist (STAS)
domain. Initial analysis showed that deletion of the R domain
almost eliminated CFTR–IRBIT interaction (Fig. 6B), the R do-
main strongly bound IRBIT (Fig. 6C), and the STAS domain
strongly bound IRBIT (Fig. 6D). We could not test the functional
consequence of binding of IRBIT to the STAS domain, because
deletion within the Slc26a6 STAS domain tested trapped the
protein in the endoplasmic reticulum.
Although deletion of the R domain reduces its surface expres-
sion, some ΔR-CFTR travels to the plasma membrane, where it
behaves as a constitutively active, cAMP-independent Cl− channel
(21, 23). This behavior allowed us to test the role of the R domain
in the activation of CFTR by IRBIT. We found that IRBIT acti-
vated the current of full-length CFTR that was inhibited by the
speciﬁc CFTR inhibitor CFTRinh-172 (Fig. 6 E and F), conﬁrming
previously reported results (16). Importantly, the largely consti-
tutive current of ΔR-CFTR was inhibited by 5 μM CFTRinh-172,
and the activity ofΔR-CFTR was not activated by IRBIT (Fig. 6 E
and F). These interesting ﬁndings suggest that the regulatory
module identiﬁed in the present work may be a general module
that integrates regulatory modalities in other transporters involved
in ﬂuid and electrolyte secretion in secretory epithelia.
Conclusions
The present ﬁndings identify a regulatory module within the N
terminus of the majority of the NBCs in the NCBT superfamily
(16 of 25 isoforms) that may be present in other transporters as
well. Importantly, key regulatory modalities are congregated
within the module to regulate both the inhibition and activation
of electrogenic and electroneutral NBCs. Indeed, this module has
been shown to function as an autoinhibitory domain (2) that
keeps the transporters, and thus the secretion/salvage mediated
by these transporters, in an inactive state. Our ﬁndings suggest
that recruitment of SPAK by the WNK kinases to these trans-
porters stabilizes autoinhibition by the AID, given that mutations
of Ser65 that are phosphorylated by SPAK affect basal activity,
increasing activity by Ser/Ala mutations and suppressing activity
by Ser/Asp mutations. This autoinhibitory state was reversed by
Fig. 4. Regulation of NBCn1-A by the WNK/SPAK and IRBIT/PP1 pathways.
(A) Sample traces. (B) Summary of data, showing that NBCn1-A is activated
by IRBIT and PP1, but not by IRBIT(ΔPEST) or IRBIT(ΔC-C), and is inhibited by
the PP1 inhibitors I2 and tautomycin. NBCn1-A is inhibited by SPAK, and this
inhibition is reversed by IRBIT and PP1.
Fig. 5. Effects of the arginine mutations on activation of NBCn1-A by IRBIT
and PIP2. (A–C) Activation of NBCn1-A by IRBIT and PIP2 is nonadditive (A
and C) and is eliminated by the 3R/3A mutation (B and C). (D) The NBCn1-A
(3R/3A) mutation also prevents interaction with IRBIT. (E) SPAK reduces
surface expression of NBCn1-A, which is reversed by IRBIT, and the effect of
SPAK on surface expression is eliminated by the 3R/3A mutation.
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both IRBIT and PIP2. We were somewhat surprised to ﬁnd that
the functions of IRBIT and PIP2 are nonadditive but appear to be
complementary, owing to their interaction with the same posi-
tively charged conserved arginines within the AID. IRBIT and
IP3 are known to compete for binding to the IP3-binding pocket
of the IP3 receptors (24), and we found that IRBIT and the IP3
containing PIP2 interacted with the same site in the AID of the
NBCs. The complementary action of PIP2 may serve as a backup
mechanism to ensure activation of the transporters on demand;
however, it is more likely that under physiological conditions,
both mechanisms cooperate to regulate the activity of the
transporters, thereby increasing the ﬁdelity of the activated
state. The identiﬁcation of a similar module in CFTR and
Slc26a6 raises the possibility that this module may function in
other transporters as well. Exploring the roles of this module
in the various transporters and in the regulation of epithelial
transport will be of interest.
Methods
Plasmid Construction and Solutions. The p3xFLAG-CMV-7.1/IRBIT, pEGFP-C1/
NBCe1-B, pCDNA 3.1+/NBCn1-A, and ΔR-CFTR constructs have been de-
scribed previously (16, 23, 25). The arginine mutants and deletions in NBCe1-B
and NBCn1-A were generated by PCR with Pfu DNA polymerase (Agilent),
using primers to change speciﬁc regions. All constructs were veriﬁed by
determining the insert size after treatment with restriction enzyme and
sequencing of the entire ORFs to ensure the absence of unwanted muta-
tions. The standard bath solution (solution A) contained 140 mM NaCl, 5 mM
KCl, 1 mMMgCl2, 1 mM CaCl2, 10 mM Hepes (pH 7.4 with NaOH), and 10 mM
glucose. Na+-free solutions were prepared by replacing Na+ with NMDG.
HCO3
–-buffered solutions were prepared by replacing 25 mM Na+ anion with
25 mM Na+-HCO3
– and reducing Hepes to 2.5 mM. HCO3
–-buffered solutions
were gassed with 5% (vol/vol) CO2 and 95% (vol/vol) O2. The osmolarity of
all solutions was adjusted to 310 mOsmol with the major salt.
pHi Measurements. pHi was measured with 2′,7′-bis-(carboxyethyl)-5-(and-
6)-carboxyﬂuorescein (BCECF) (Teﬂab) by recording BCECF ﬂuorescence at
dual-excitation wavelengths of 490 and 440 nm and collecting the light
emitted at wavelengths above 530 nm. HeLa cells grown on coverslips and
transfected with the indicated plasmids were loaded in the chamber with
BCECF through a 10-min incubation at room temperature with 5 μMBCECF/AM.
Subsequent pH measurements were at 37 °C. After stabilization of the ﬂuo-
rescence, the cells were perfused with solution A for at least 10 min before
start of pHi measurements. NBC activity was measured by incubating the cells
with 10 μM S-(N-ethyl-N-isopropyl) amiloride to inhibit all Na+/H+ exchangers
and in Na+-free, HCO3
–-buffered media to acidify the cytosol. NBC activity was
initiated by perfusing the cells with HCO3
–-buffered media containing 140 mM
Na+. NBC activity was determined from the slopes of ﬁrst derivatives of the
ﬁrst 30–45 s of pHi increase and is expressed as percent fold change relative to
the activity measured with WT NBCs in the same experiments.
Intracellular Delivery of PIP2 in Intact Cells. To deliver PIP2, a mixture of his-
tone H1 carriers and PIP2 di-C16 (obtained from Echelon) at a 1:1 molar ratio
was brieﬂy vortexed and then incubated for 10 min at room temperature,
according to the manufacturer’s instructions. Once formed, the complex was
diluted to the desired ﬁnal concentration of 10 μM with cell culture media.
The cells were incubated with the mixture for 50 min at 37 °C in a humidiﬁed
incubator before loading with BCECF and measurement of pHin.
Surface Expression and Coimmunoprecipitation. For biotinylation experiments
to determine transporter surface expression, cells were incubated with 0.5 mg/
mLEZ-LINK Sulfo-NHS-LC-biotin (ThermoScientiﬁc) for 30min at 0 °C, incubated
with 100 mM glycine for 10 min, washed with PBS, and lysed. Biotinylated
NBCe1-B and NBCn1-A were isolated with avidin beads via incubation of
lysates for 2 h at room temperature and then recovered by heating at 37 °C for
30 min. Lysates were prepared by disruption of cells in ice-cold lysis buffer for
15–30 min and collection by centrifugation for 20 min. The lysis buffer con-
tained 20 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% (vol/vol) Triton X-100, and
a protease inhibitor mixture. For analysis of phosphoproteins, the lysis buffer
was supplemented with a phosphatase inhibitor mixture.
For coimmunoprecipitation, extracts were incubated with anti-Flag
and anti–β-actin (Sigma-Aldrich), anti-GFP (Invitrogen), and anti–NBCn1-A
(Abcam) antibodies and incubated with protein G Sepharose beads (Invi-
trogen) for 2 h at 0 °C. Beads were collected and washed three times with
lysis buffer, and proteins were recovered by heating in SDS sample buffer at
Fig. 6. CFTR and Slc26a6 sites that mediate regulation by IRBIT. (A) The sequence within the CFTR R domain and the sequence within the Slc26a6 STAS
domain that show signiﬁcant homology with the NBC regulatory module, identiﬁed using the sequence in Fig. 1A as a template. (B) Deletion of the R domain
inhibits CFTR–IRBIT interaction. (C) The R domain (RD) interacts with IRBIT. (D) IRBIT interacts with the Slc26a6 STAS domain. (E) Current traces in HEK cells
expressing CFTR (Left) or ΔR-CFTR (Right) and with and without IRBIT and stimulated with 5 μM forskolin. The CFTR current is potently activated by IRBIT. The
ΔR-CFTR current is minimally activated further by forskolin and is inhibited by CFTRinh-172, but is not activated by IRBIT. (F) Mean ± SEM of experimental data.







37 °C for 30 min. The heated samples were subjected to SDS/PAGE and
subsequently transferred to nitrocellulose membranes.
NBCe1-B Current Measurement in HeLa Cells. NBCe1-B activity was measured in
transiently transfected HeLa cells by whole-cell current recording at room
temperature. In brief, HeLa cells transfected with NBCe-1 B and with or
without IRBIT were plated on 35-mmPetri dishes on the day of the experiment
and incubated with culture media for at least 2 h to allow attachment to the
dish. Patch clamp pipettes were pulled from glass capillaries (G120F-3; Warner
Instruments) using a vertical puller (model PC-10; Narishige). These pipettes
had a resistance of 5–7 mega-Ωwhen ﬁlled with KCl-based pipette solution. A
reference Ag-AgCl electrode was connected to the bath solution via an agar
bridge ﬁlled with 140 mM KCl. The current was obtained by rapid (400 ms)
alternation of membrane potential from −60 to +60 mV every 2 s from
a holding potential of 0 mV. The current recorded at −60 mV was used to
calculate current density as pA/pF. An Axopatch 200B patch-clamp ampliﬁer
and Digidata 1440A and pClamp 10 software (all from Molecular Devices)
were used for data acquisition and analysis. The whole-cell currents were
ﬁltered at 1 kHz and sampled at 10 kHz. The cell capacitance was 15–25 pF.
The pipette solutions contained 140 mM CsCl, 2 mMMgCl, 1 mM ATP, 0.2 mM
EGTA and 10 mM Hepes (adjusted to pH 7.3 with CsOH), or with the major
salts replaced with 140 mM KCl, 0.2 mM EGTA, and 10 mM Hepes (adjusted to
pH 7.3 with KOH) or 140 mM NMDG-Glu, 10 mM NMDG-Cl, 0.2 mM EGTA,
and 10 mM Hepes. The Hepes-buffered bath solution contained 140 mM
NaCl, 5 mM KCl, 1 mMMgCl2, 1 mM CaCl2, 10 mM glucose, and 10 mM Hepes
(adjusted to pH 7.4 with NaOH). The HCO3
−-buffered solution was prepared
by replacing 25 mM NaCl with an equimolar amount of NaHCO3, and the
solution was equilibrated with 5% (vol/vol) CO2/95% (vol/vol) O2. All experi-
ments were performed at room temperature.
Measurement of ΔR-CFTR Current. The CFTR and ΔR-CFTR current was mea-
sured in HEK cells transfected with the indicated plasmid exactly as described
previously (16, 23). Stock solution of water-soluble PIP2 (1 mM) was prepared
in deionized water and stored at −20 °C under argon until use. The PIP2
derivative P-4506 was obtained from Ethelon Biosciences. Fresh PIP2 was
added to the pipette solution, and NBCe1-B activity was measured 2 min
after the whole-cell conﬁguration was established. A 100 mM stock solution
of DIDS (Molecular Probes) dissolved in DMSO was freshly prepared and
diluted to a ﬁnal concentration of 50 μM in the relevant solutions.
Statistics. All results are given as mean ± SEM. Signiﬁcance was analyzed
using the Student t test or ANOVA.
Structural Prediction and Protein Modeling. The entire N terminus of human
NBCe1-B, consisting of 400 amino acids (National Center for Bio-
technology Information reference sequence NP_001091954), was sub-
mitted to the ROBETTA online full-chain protein structure prediction
server (26). According to the server parsing hierarchy protocol, the
“Ginzu” domain prediction method was used initially, and assigned two
domains separated by a cut-linker around residues 81–82. One domain
spanning residues 82–400 was identiﬁed by “blast” to be homologous to
the cytoplasmic domain of the human erythrocyte band 3 cytoplasmic
domain (Protein Data Bank ID code 1HYN), with a conﬁdence score of
57.00. No homology was identiﬁed for residues 1–81, and thus these
were assigned as a multiple sequence alignment cluster by the server for
de novo modeling. A de novo model for residues 1–81 was generated
(conﬁdence score, 2.095). Five ﬁnal models were generated by an as-
sembly of the two domains and side chain repacking. The models were
very similar, with differences in the tilt of the AID. We selected the
model in which the AID was linked to the homologous domain with
a hinge that might allow rotation during activation by IRBIT. The coor-
dinates provided by the ROBETTA server were used to generate the ﬁnal
model (Fig. S2B) with PyMol software (Schrödinger).
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